A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease

Ondo, William G.; Hunter, Christine; Moore, Warren H.

doi:10.1212/01.wnl.0000101713.81253.4c

Cited by 218 publications

(190 citation statements)

References 26 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…Pronounced hypersalivation may be attenuated using anticholinergic drugs [262] or by local injection of botulinum toxin A into the salivary glands as has been demonstrated in patients with ALS and Parkinson’s disease [268,269,270]. Botulinum toxin A applied to the superior esophageal sphincter may reduce dysphagia due to an elevated sphincter tone [271].…”

Section: Dysphagiamentioning

confidence: 99%

Symptomatic Treatment of Multiple Sclerosis

2006

View full text Add to dashboard Cite

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures.

show abstract

Section: Dysphagiamentioning

confidence: 99%

Symptomatic Treatment of Multiple Sclerosis

2006

View full text Add to dashboard Cite

show abstract

“…Xerostomia is one of the manifestations of botulism, which led to the introduction of BTX to treat sialorrhea and drooling. BTX-A treated for sialorrhea associated with Parkinson's disease had a very favorable outcome when injected into parotids or both parotid and submandibular glands to inhibit the stimulation of cholinergic receptors [89][90][91][92]. Fuster et al injected BTX into parotid submandibular gland or both with doses varying from 10 TO 100 units, which resulted in reduction in saliva production which lasted for 6 months [93].…”

Section: Salivary Secretory Disordersmentioning

confidence: 99%

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Kumar

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used for therapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible. The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanism of action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for several conditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists can safely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offers exciting treatment options for dentists and patients in the future.

show abstract

“…Por lo mismo, el tratamiento con anticolinérgicos es inefectivo. La toxina botulínica (parótida, submandibular) podría disminuir la salivación pero es técnicamente compleja pudiendo, por otra parte, aumentar la disfagia y la probabilidad de infecciones de la cavidad bucal 34 .…”

Section: Disfagiaunclassified